A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Active:	Yes
Cancer Type:	Stomach/ Gastric Cancer	NCT ID:	NCT04931654
Trial Phases:	Phase I Phase II	Protocol IDs:	D9570C00001 (primary) NCI-2022-01956 152970 2021-000036-57
Eligibility:	18 - 130 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT04931654

Summary

This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3
bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with
advanced solid tumors.

Objectives

This first time in patients, open-label, multi-centre study will have AZD7789
administered intravenously (IV) to participants with advanced solid tumors. This study
will have 2 parts: Part A which will have dose escalation cohorts and Part B which will
have the dose expansion cohorts.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.